DiscoverCOR2ED - Obstetrics & Gynecology Medical ConversationEndometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective
Endometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective

Endometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective

Update: 2023-12-06
Share

Description

Join world-renowned gynaecological oncology experts Dr Domenica “Ketta” Lorusso and Dr Mansoor Mirza as they explore the changing landscape of systemic treatment in endometrial carcinoma. Single-agent immunotherapies (pembrolizumab and dostarlimab), and now immunotherapy and antiangiogenic therapy combinations (pembrolizumab and lenvatinib), are transforming treatment pathways, with OS benefits in the second-line now achievable. They offer tips for managing the toxicity of these novel therapeutic options and set the stage for 2023, a year which promises a paradigm shift in the use of systemic treatments in this once underserved malignancy.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Endometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective

Endometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective

COR2ED Medical Education